MORRISVILLE – Syneos Health, which recently invested $400 million in an acquisition, now has another $600 million to possibly pursue more deals.
The provider of contract research and commercial organization services to life science clients on Tuesday closed on a $600 million deal for notes that come due in 2029. Syneos (NYSE: SYNH) increased the offer from $500 million as originally announced last week.
So how will the funds be used?
“The net proceeds of the offering will be used for general corporate purposes, including the funding of acquisitions, and for repayment of indebtedness,” the company said in a statement.
Inside ever-growing Syneos Health’s $400M acquisition of Synteract
